SAB Biotherapeutics
SABS
SABS
25 hedge funds and large institutions have $3.38M invested in SAB Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Holders
25
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$29.9K | |
| 2 | +$20.8K | |
| 3 | +$18.6K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.51K |
| 5 |
Renaissance Technologies
New York
|
+$1.75K |
Top Sellers
| 1 | -$358K | |
| 2 | -$29.9K | |
| 3 | -$26.8K | |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.3K |
| 5 |
Millennium Management
New York
|
-$22.1K |
